ArticleBMC endocrine disorders2025
Circulating miR-4454 as a potential biomarker for the diagnosis of T2DM and the prediction value of comorbidity and complications in T2DM.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA Signatures in Cardiometabolic Disorders as a Next-Generation Diagnostic Approach: Current Insight.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveT2DM (type 2 diabetes mellitus) is a chronic metabolic disease that seriously affects human health. Abnormal expression of microRNAs has been reported to play an important role in disease diagnosis. This study aimed to investigate the predictive value of miR-4454 for T2DM and possible risk factors for comorbidity and complications (CC) of T2DM.
methodsBaseline information was collected from a total of 206 subjects including 109 T2DM patients (T2DM group) and 97 healthy individuals (healthy control group), and miR-4454 expression levels were assessed by qRT-PCR. A chi-squared test and a t-test were used to assess the difference in miR-4454 expression of T2DM and healthy subjects. The predictive value of miR-4454 on T2DM was evaluated by receiver operating characteristic (ROC). Potential risk factors for CC of T2DM were predicted by multivariate logistic regression analysis.
resultsSignificant downregulation of miR-4454 was observed in the T2DM group. The predictive value of miR-4454 for T2DM was verified by the ROC curve. MiR-4454 expression in the T2DM group was negatively correlated with fasting blood glucose (FBG), glycated hemoglobin (HbA1c), homeostasis model-insulin resistance index (HOMA-IR), total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), and positively correlated with the levels of adiponectin (ADI) and peroxisome proliferator-activated receptor gamma (PPAR-γ). Multivariate logistic regression analysis suggested that miR-4454, FBG, HbA1c, HOMA-IR, TC, TG, and LDL-C could be considered risk factors for CC of T2DM.
conclusionsThe expression level of miR-4454 showed a diagnostic value for T2DM and could serve as a risk factor for the occurrence of CC in T2DM. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.